Shares of Derma Sciences Inc. (NASDAQ:DSCI) saw strong trading volume on Thursday . 443,001 shares traded hands during trading, an increase of 554% from the previous session’s volume of 67,705 shares.The stock last traded at $4.85 and had previously closed at $4.31.

Separately, Zacks Investment Research downgraded Derma Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Derma Sciences presently has an average rating of “Hold” and an average target price of $7.45.

The firm has a 50 day moving average of $4.09 and a 200 day moving average of $3.62. The firm’s market capitalization is $123.48 million.

Derma Sciences (NASDAQ:DSCI) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The business earned $20.20 million during the quarter, compared to analyst estimates of $20.60 million. On average, analysts forecast that Derma Sciences Inc. will post ($0.20) EPS for the current year.

A hedge fund recently raised its stake in Derma Sciences stock. Jennison Associates LLC raised its stake in shares of Derma Sciences Inc. (NASDAQ:DSCI) by 22.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,407,506 shares of the company’s stock after buying an additional 261,818 shares during the period. Jennison Associates LLC owned approximately 5.45% of Derma Sciences worth $6,432,000 as of its most recent filing with the SEC.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.